The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapies for the Treatment of Intermediate and Advanced Hepatocellular Carcinoma Unsuitable for Transarterial Chemoembolization
Hao-Huan Tang, Ming-Qing Zhang, Zi-Chen Zhang, Chen Fan, Yong Jin, Wei-Dong Wang · 2023
Read The Safety and Efficacy of Hepatic Arterial Infusion Chemotherapy Combined with PD-(L)1 Inhibitors and Molecular Targeted Therapies for the Treatment of Intermediate and Advanced Hepatocellular Carcinoma Unsuitable for Transarterial Chemoembolization by Hao-Huan Tang, Ming-Qing Zhang, Zi-Chen Zhang, Chen Fan, Yong Jin, Wei-Dong Wang (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10725683.txt.
Description
Hao-Huan Tang and co-authors test a triple drug mix for liver cancer in a 2023 study. The patients had mid or late stage cancer that could not get the standard artery-blocking care. The mix joins chemo pumped into the liver's artery, immune drugs that free the body's defenses, and targeted pills. Records came from two centers for patients treated from 2020 to 2021.
The group held 55 patients. Middle survival reached 15 months, and the middle span before growth was 10 months. Tumors shrank in 43.6 percent of patients, and disease was held in 61.8 percent. Side effects hit 58.2 percent of patients, with a fifth of cases at strong grades. Liver strain signs were the most common. No deaths came from the care itself.
Catalog record
| CREATOR | Hao-Huan Tang, Ming-Qing Zhang, Zi-Chen Zhang, Chen Fan, Yong Jin, Wei-Dong Wang |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 28 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |